Miostin (Neostigmine Methylsulfate)

Neostigmine methylsulfate is a reversible acetylcholinesterase inhibitor. By binding to the enzyme acetylcholinesterase, it prevents the breakdown of acetylcholine, leading to increased concentrations of this neurotransmitter at neuromuscular junctions and in autonomic synapses. The elevated acetylcholine enhances muscle contraction and stimulates smooth‑muscle activity, which underlies its therapeutic effects.

The dosage of Miostin is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and clinical response. Healthcare professionals calculate the appropriate amount and route (intravenous, intramuscular, or subcutaneous) and adjust as needed during treatment. Patients should follow the prescriber's instructions and not alter the dose on their own.

Safety data for neostigmine methylsulfate in pregnancy and lactation are limited, and the product is generally classified as a category where benefits must be weighed against potential risks. Clinicians should consider alternative therapies when possible and use Miostin only if clearly needed. Breastfeeding mothers should consult their physician before use.

To request Miostin, visit the product page on gnhindia.com, enter the desired quantity, and submit the inquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing a quotation, availability details, shipping options (including cold‑chain if required), and necessary import documentation.

Miostin (neostigmine methylsulfate) is a quaternary ammonium compound, offering rapid onset when administered intravenously and limited ability to cross the blood‑brain barrier, reducing central side effects compared with physostigmine. Compared with pyridostigmine, neostigmine has a shorter duration of action, making it suitable for acute reversal of neuromuscular blockade rather than chronic management.

Miostin should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the product from direct sunlight, moisture, and extreme temperature fluctuations. Do not freeze the solution. Follow any additional handling instructions provided by the supplier to maintain product integrity.

Miostin is supplied as a sterile injectable solution for intramuscular, intravenous, or subcutaneous injection. The route and rate of administration are determined by the treating physician, often based on the clinical situation—e.g., rapid intravenous bolus for neuromuscular blockade reversal or slower infusion for myasthenic patients. Proper aseptic technique and appropriate dilution, if required, should be observed.

The most critical adverse reactions include cholinergic crisis, severe bradycardia, bronchospasm, hypotension, and allergic anaphylaxis. These events can be life‑threatening and require immediate medical intervention, such as atropine administration for bradycardia or airway support for bronchospasm. Patients should be monitored closely during and after dosing.

Miostin is contraindicated in individuals with known hypersensitivity to neostigmine or any component of the formulation. It should be used with caution, or avoided, in patients with severe asthma, chronic obstructive pulmonary disease, bradyarrhythmias, or recent myocardial infarction, as the cholinergic effects may exacerbate these conditions. Clinical judgment determines suitability.